Rod discusses the contrasting fortunes of companies in the current market, particularly those launching products with modest peak sales projections. He highlights the difficulties in securing necessary funding amidst heightened risk aversion. Despite the challenges faced by listed funds, he believes there are still valuable opportunities in biotech, especially for those who can navigate the complexities of the market.
